10% OFF
language: english
Publisher: TAYLOR & FRANCIS LTD, October of 2023 ‧
71,64€
10% OFF CARD
free shipping
Sell ​​your book
The focus of this book is on how the US FDA will approve biosimilar drugs. The European scene is well developed with specific guidelines that are already in place. However, these guidelines do not apply to the thinking of the FDA in approving these products.

Biosimilarity

The Fda Perspective

by Sarfaraz K. (Therapeutic Proteins International, Llc, Usa) Niazi

Property Description
ISBN: 9781032652351
Publisher: TAYLOR & FRANCIS LTD
Release Date: October of 2023
Language: English
Dimensions: 178 x 254 x 20 mm
Cover: Softcover
Pages: 436
Format: Book
Categories: Books in English > Science > Biology
Books in English > Engineering > General Engineering
Books in English > Medicine > General Medicine
Books in English > Others
EAN: 9781032652351